Live data · NADAC + Part D CY24 · reviewed daily

Hydralazine and Isosorbide Dinitrate (BiDil)

Nitrate Vasodilator class · 2 generic manufacturers · 2 ANDAs filed at FDA.

First FDA approval2012-12-05
Generic availableYes · 2 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.714/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2.53
Across all dosage forms in distribution.
Highest NADAC
$4.35
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Hydralazine and Isosorbide Dinitrate used for?

Hydralazine and Isosorbide Dinitrate is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Hydralazine and Isosorbide Dinitrate?

Yes. 2 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Hydralazine and Isosorbide Dinitrate?

Across 329 Part D plans, Hydralazine and Isosorbide Dinitrate averages $2.53/unit (NADAC). Lowest available: $0.714/unit. Highest in distribution: $4.35/unit.

Is Hydralazine and Isosorbide Dinitrate on the FDA shortage list?

No. Hydralazine and Isosorbide Dinitrate is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.